Literature DB >> 20080321

X-linked ichthyosis: an oculocutaneous genodermatosis.

Neil F Fernandes1, Camila K Janniger, Robert A Schwartz.   

Abstract

X-linked ichthyosis (XLI) is an X-linked recessive disorder of cutaneous keratinization with possible extracutaneous manifestations. It was first described as a distinct type of ichthyosis in 1965. XLI is caused by a deficiency in steroid sulfatase activity, which results in abnormal desquamation and a retention hyperkeratosis. XLI is usually evident during the first few weeks of life as polygonal, loosely adherent translucent scales in a generalized distribution that desquamate widely. These are quickly replaced by large, dark brown, tightly adherent scales occurring primarily symmetrically on the extensor surfaces and the side of the trunk. In addition, extracutaneous manifestations such as corneal opacities, cryptorchidism, and abnormalities related to contiguous gene syndromes may be observed. Diagnosis of XLI is usually made clinically, as the histopathology is nonspecific, but confirmation may be obtained through either biochemical or genetic analysis. Treatment should focus on cutaneous hydration, lubrication, and keratolysis and includes topical moisturizers and topical retinoids. Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080321     DOI: 10.1016/j.jaad.2009.04.028

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  21 in total

1.  Pre-Descemet corneal dystrophy and X-linked ichthyosis associated with deletion of Xp22.31 containing the STS gene.

Authors:  Crystal Hung; Reed I Ayabe; Cynthia Wang; Ricardo F Frausto; Anthony J Aldave
Journal:  Cornea       Date:  2013-09       Impact factor: 2.651

Review 2.  New developments in the molecular treatment of ichthyosis: review of the literature.

Authors:  M D W Joosten; J M K Clabbers; N Jonca; J Mazereeuw-Hautier; A H Gostyński
Journal:  Orphanet J Rare Dis       Date:  2022-07-15       Impact factor: 4.303

Review 3.  Role of cholesterol sulfate in epidermal structure and function: lessons from X-linked ichthyosis.

Authors:  Peter M Elias; Mary L Williams; Eung-Ho Choi; Kenneth R Feingold
Journal:  Biochim Biophys Acta       Date:  2013-11-27

4.  Lamellar ichthyosis with rickets.

Authors:  Raafia Ali; Shahbaz Aman; Muhammad Nadeem
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

5.  Behavioural and Psychiatric Phenotypes in Men and Boys with X-Linked Ichthyosis: Evidence from a Worldwide Online Survey.

Authors:  Sohini Chatterjee; Trevor Humby; William Davies
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

6.  A pharmacological mouse model suggests a novel risk pathway for postpartum psychosis.

Authors:  Trevor Humby; Ellen S Cross; Lauren Messer; Silvia Guerrero; William Davies
Journal:  Psychoneuroendocrinology       Date:  2016-09-28       Impact factor: 4.905

7.  Insights into rare diseases from social media surveys.

Authors:  William Davies
Journal:  Orphanet J Rare Dis       Date:  2016-11-09       Impact factor: 4.123

8.  Medical and neurobehavioural phenotypes in male and female carriers of Xp22.31 duplications in the UK Biobank.

Authors:  Samuel J A Gubb; Lucija Brcic; Jack F G Underwood; Kimberley M Kendall; Xavier Caseras; George Kirov; William Davies
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

Review 9.  The Regulation of Steroid Action by Sulfation and Desulfation.

Authors:  Jonathan W Mueller; Lorna C Gilligan; Jan Idkowiak; Wiebke Arlt; Paul A Foster
Journal:  Endocr Rev       Date:  2015-07-27       Impact factor: 19.871

10.  Steroid Sulfatase Deficiency and Androgen Activation Before and After Puberty.

Authors:  Jan Idkowiak; Angela E Taylor; Sandra Subtil; Donna M O'Neil; Raymon Vijzelaar; Renuka P Dias; Rakesh Amin; Timothy G Barrett; Cedric H L Shackleton; Jeremy M W Kirk; Celia Moss; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2016-03-22       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.